In industrialized countries, the use of highly active antiretroviral therapy during pregnancy-and, in some instances, cesarean section before onset of labor-is encouraged, to prevent mother-to-child transmission of HIV-1 [1] ; in contrast, in the developing world, shorter and simpler antiretroviral regimens, combining maternal antenatal, intrapartum, and/or infant components, are recommended by the World Health Organization [2] . The rationale for each component relies mostly on assumptions regarding the timing of transmission, as determined by the results of virologic tests performed during the first days of life, as has been proposed by Bryson et al. [3] : in the absence of any intervention, ϳ35%-49% of the children born to HIV-infected mothers are infected by the virus-with ϳ8% becoming infected during pregnancy, ϳ15% during labor and delivery, and ϳ12%-26% during breast-feeding [4, 5] .
The risk of perinatal transmission of HIV has been linked to markers of disease progression or immune deficiency [6 -8] , high HIV load [9 -12] , occurrence of sexually transmitted diseases during pregnancy, and obstetrical factors such as prolonged rupture of mem-branes [13, 14] and vaginal delivery as opposed to elective cesarean section [8, 15, 16] . However, because previous studies frequently did not use early polymerase chain reaction (PCR) testing for HIV and used relatively small sample sizes in their clinical trials, the respective contribution that these factors make to in utero versus intrapartum transmission has rarely been examined in a large homogenous sample of patients [17] [18] [19] [20] . To better understand the respective role that these factors play in relation to the timing of transmission, we analyzed the data from a single large clinical trial of short-versus long-course zidovudine treatment in Thailand [21] .
PATIENTS, MATERIALS, AND METHODS
Patients. From 24 June 1997 to 3 December 1999, a total of 1437 antiretroviral-naive women were enrolled in Perinatal HIV Prevention Trial-1 (PHPT-1; ClinicalTrials.gov NCT00386230), a multicenter, randomized, controlled double-blind trial conducted in 27 hospitals in Thailand [21] . A 2 ϫ 2 factorial design was used to assign mothers to receive 300 mg of zidovudine twice daily from either 28 or 35 weeks gestation until labor. They were monitored at 32, 35, 38, and 40 weeks gestation and every week thereafter until delivery. At the onset of labor, they ingested 300 mg of zidovudine orally every 3 h until delivery. Infants were fed formula and were assigned to receive oral zidovudine for either 6 weeks or 3 days. After the first interim analysis, enrollment in the "short-short arm" (zidovudine treatment initiated in mothers at 35 weeks gestation and administered to infants for 3 days) was discontinued, and infants born subsequently to mothers in this arm who had not yet delivered were unblinded and were reassigned to long-course zidovudine prophylaxis. Enrollment in the other 3 arms continued. The protocol was approved by the ethics committees of the Thai Ministry of Public Health, Chiang Mai University, and the Harvard School of Public Health, and human-experimentation guidelines of the US Department of Health and Human Services were followed.
Collection of data. Preenrollment evaluation, including data on demographic characteristics and gestational age and from blood-chemistry and hematology analyses and uterine sonography, were completed between 26 and 28 weeks gestation. Before enrollment, the gestational age was determined by the attending obstetrician, on the basis of the last menstruations date, clinical exam, and results of sonography. Maternal HIV-1-RNA load in blood was measured by the Cobas Amplicor HIV Monitor Test assay (version 1.5; Roche Molecular Systems), with a detection threshold of 400 copies/mL.
HIV infection status of infants. Blood was drawn at 1 day, 6 weeks, and 4 and 6 months of age, for HIV-DNA PCR testing performed on dried blood spots by the Roche Monitor assay (version 1.5) [22] . An infant was considered to have been perinatally infected with HIV if the PCR test showed at least 2 different specimens to be positive; an infant was considered to be uninfected if the test showed at least 2 specimens obtained on separate occasions at 1-6 months of age to be negative. In the absence of breast-feeding, we followed Bryson et al. [3] by considering infants with a PCR-test result positive for HIV DNA during the first 3 days of life to have been infected during pregnancy and before the onset of labor ("in utero" transmission); infants with a PCR-test result negative for HIV-DNA during the first 3 days of life but with a later test result that was positive were considered to have been infected during labor or delivery ("intrapartum" transmission). In utero transmission was excluded from the analysis of intrapartum transmission.
After excluding infants for whom no PCR results were available and second twins, we considered 1392 infants, including 97 confirmed to have been perinatally infected (see figure 1 ). There were 13 infected infants whose first available PCR-test result was positive but was obtained after 3 days of life; they were included only in the analysis of the overall transmission. Finally, we excluded 19 infants from the analysis of both intrapartum and overall transmission because their HIV-negative status was not confirmed; 7 of them had only a single PCR test performed during the first 3 days of life, and 12 of them only a single PCR test after 1 month of life (figure 1).
Statistics. Values for continuous variables are presented as medians and interquartile ranges, and values for categorical variables are presented as percentages. The standard clinical thresholds of 200 cells/mm 3 for absolute CD4 cell count, 15% for CD4 cell percentage, and 1.5 mg/dL for serum creatinine were used, other continuous variables were categorized into quartiles, and HIV-1-load thresholds were rounded to 2000, 10,000, and 35,000 copies/mL.
For analysis of the role played by zidovudine prophylaxis, we adopted an "as treated" approach. We categorized the actual gestational age at initiation of zidovudine prophylaxis (regardless of the original random assignment) and used the minimum between the 2 peaks of its bimodal distribution, 31.4 weeks gestation, to define 2 groups who received either "early" or "delayed" zidovudine prophylaxis. We excluded cases with poor adherence, as assessed by pill count and syrup-bottle weight (19 mothers and 22 infants, in whom there were no cases of transmission, took Ͻ75% of the prescribed zidovudine doses). We included in this analysis the 87 cases that we had excluded from the original clinical-trial analysis, with the treatment reassignment made after the first interim analysis.
We separately looked at the association between all of the variables listed in table 1 and in utero and intrapartum transmission. For the multivariate logistic-regression analysis of risk factors, we selected the variables associated with the transmission risk, provided that their P value was Ͻ0.3 in the univariate analysis using the Fisher test for dichotomous variables or the likelihood ratio 2 for multiple category variables. We used a backward approach to variable selection and the maximum likelihoodratio test [23] , first considering the variables known at baseline.
We then tested one by one the association between each variable known during the last trimester of pregnancy or at delivery and the transmission risk after adjustment for the baseline variables that remained independently associated with the transmission risk. For analysis of the role played by induction of labor, we also adjusted for the main indications-namely, "premature rupture of membranes" and "prolonged labor." We also tested for interactions between the variables that remained significantly associated with the transmission risk. The same procedure was used for the analysis of the risk factors for in utero, intrapartum, and overall transmission. The results of the logistic regression analyses were expressed as odds ratios (ORs) and their 95% confidence intervals (CIs). All reported P values are 2-sided. We considered an association to be statistically significant if the P р .05. No correction was made for multiple comparisons.
RESULTS
Of the 97 perinatal transmissions, 35 and 49 met the definition of in utero and intrapartum transmission, respectively (figure 1). The characteristics of the women, deliveries, and infants considered in this analysis are displayed in table 1. Almost half of the women had had no previous pregnancies, and Ͻ2% were smokers or drug users. Table 2 displays the results of the univariate analysis for all factors significantly associated with either the in utero, intrapartum, or overall perinatal risk of transmission of HIV-1. With few exceptions, variables associated with overall transmission tracked with the variables associated with either in utero or intrapartum transmission. No transmission occurred in the 105 women who had baseline HIV-1 levels Ͻ400 copies/mL.
A total of 18% of the women underwent cesarean section, with 97% of these procedures occurring after the onset of labor. There was no association between cesarean section and risk of transmission.
In women who experienced premature rupture of membranes, the estimated risk of intrapartum transmission was 7.7% (95% CI, 2%-21%) if labor was induced and 6.9% (95% CI, 1%-23%) if it was not; in women who experienced prolonged labor, the risk was 13.3% (95% CI, 2%-40%) and 2.6% (95% CI, 0.3%-9%), respectively. Table 3 shows the results of the multivariate logistic regression analysis. Variables remaining independently associated with in utero transmission were baseline maternal HIV-1 load Ͼ35,000 copies/mL and delayed maternal zidovudine prophylaxis. Variables remaining independently associated with intrapartum transmission were baseline HIV-1 load Ͼ10,000 copies/mL (adjusted OR, 3.8 for 10,000 -35,000 copies/mL and 7.1 for Ͼ35,000 copies/mL), induction of labor, and premature labor with tocolysis. Variables remaining independently associated with overall transmission were high baseline HIV-1 load, high baseline level of serum creatinine, premature labor with tocolysis, prematurity, and low birth weight.
In an additional analysis restricted to full-term infants with low birth weight, the estimated risks of in utero, intrapartum, and overall transmission were 4.4%, 3.8%, and 8.1%, respec- tively, in low-birth-weight full-term infants, versus 2.2%, 3.3%, and 6.1%, respectively, in normal-birth-weight full-term infants (P ϭ 0.18, 0.78, and 0.41, respectively). When adjusted for baseline HIV-1 load and duration of zidovudine treatment, the association with in utero, intrapartum, and overall transmission was not significant (P ϭ 0.32, 0.91, and 0.62, respectively). NOTE. IQR, interquartile range. a Reasons reported: fetal distress (1%), intrauterine growth retardation (2%), post-date pregnancy (Ͼ42 weeks), other fetal indications (7%), insufficient cervical dilatation (5%), premature rupture of membranes (31%), chorioamnionitis (1%), hypertension (3%), diabetes (1%), fever (3%), prolonged labor (29%), and other maternal indications (15%).
DISCUSSION
The separate analysis of the risk of in utero or intrapartum transmission of HIV-1 shows that, except for very high baseline HIV-1 load, independent risk factors differ according to the time of transmission. High baseline HIV-1 load was strongly associated with both in utero and intrapartum transmission, but the threshold was higher for in utero transmission (35,000 copies/ mL) than for intrapartum transmission (10,000 copies/mL). In contrast, delayed initiation of maternal zidovudine prophylaxis was associated only with in utero transmission.
Of the events during the last trimester of pregnancy or at delivery, induction of labor and premature labor with tocolysis were associated with intrapartum transmission, after adjust- b Zidovudine-prophylaxis groups were defined as "as treated" (see Patients, Materials, and Methods). c ORs were also adjusted for premature rupture of membranes and prolonged labor.
ment for factors known at baseline. Although the presence of specific risk factors occurring early enough during pregnancy can prompt specific preventive interventions, it is not always possible to implement effective interventions to prevent or counteract the effects of late-occurring risk factors; moreover, it is difficult to determine whether the latter have a direct causal relationship to transmission. Three factors that were not independently and significantly associated with either in utero or intrapartum transmission were found to be associated with overall transmission: prematurity, low birth weight, and, unexpectedly, elevated levels of creatinine. However, when we restricted the analysis to the full-term infants, the association between low birth weight and transmission was not significant, suggesting that growth restriction was not, per se, a risk factor of transmission. Also, only 10 women had creatinine levels Ͼ1.5 mg/dL, which limited our ability to further investigate this observation.
There are limitations to the working definition of the time of transmission. The delay between HIV contamination of the fetus or infant and the establishment of an irreversible infection that can be detected by a PCR test for HIV DNA in blood may show interindividual variation. In addition, the definition of in utero and intrapartum transmission uses the time of delivery as the reference time point and ignores the duration of labor and the role played by antiretroviral treatments that could prolong the delay before an infection becomes detectable [24] . However, the study's sample size was large, and it included a significant number of transmissions, thereby decreasing the effects of misclassification. In addition, the results are consistent with our current understanding of the mechanisms of perinatal transmission. As expected, factors impinging on gestation, such as early or late maternal zidovudine prophylaxis, impacted only in utero transmission, whereas factors affecting the process of delivery, such as induction of labor or premature labor with tocolysis, were associated with intrapartum transmission.
Because blood specimens were not collected immediately after the birth of 13 of the 97 HIV-infected infants, their HIV status at birth could not be determined, and this could have biased the results; however, when all of these 13 cases were considered to be in utero or intrapartum transmissions, the conclusions of the multivariate analysis were not changed (data not shown).
Although there were differences between the conditions of the originally published clinical-trial intent-to-treat analysis [21] and the present analysis of the treatment effect, we found, in both analyses, that delayed maternal zidovudine prophylaxis was associated with significantly higher in utero transmission (in this analysis, 3.9% vs. 1.4%). In utero transmission rates of 5%-13.9% have been reported when no maternal zidovudine prophylaxis has been offered to pregnant women [11, 25] , even when potent antiretroviral drugs such as nevirapine [26, 27] or zidovudine plus lamivudine [28] have been administered during labor. Maternal zidovudine prophylaxis initiated at various times after the beginning of the third trimester has been associ- ated with in utero transmission rates of 4.8% (when such prophylaxis is initiated at 36 weeks gestation, in a study in Thailand [25] ) and 3.5% (when it is initiated at 34 weeks gestation, in a study in Botswana [29] ). In contrast, the present study found that the in utero transmission rate in women in whom prophylaxis was initiated early during pregnancy was 1.4%, which is close to the rates reported by other studies that have similar prophylaxis-initiation times (Pediatric AIDS Cliical Trials Group protocol 185 [30] , PHPT-2 [31] ). Most important, higher-potency regimens, when started later, cannot fully substitute for the early initiation of prophylaxis, as is suggested by the 4.1% and 5.4% in utero transmission rates reported by the PETRA (Perinatal Transmission) and SIMBA (Stopping Infection from Mother-to-Child via Breastfeeding in Africa) studies, where the combinations of zidovudine plus lamivudine and zidovudine plus didanosine, respectively, were initiated at 36 weeks gestation [28, 32] ; these results support the recent change in World Health Organization guidelines, which recommend that antiretroviral prophylaxis be initiated at 28 weeks gestation [33] .
In the present study, intrapartum transmission was strongly associated with an HIV-1 load Ͼ10,000 copies/mL, a threshold that included half of the women in the study. This finding provides a rationale for interventions to decrease the exposure of the fetus/neonate to HIV-1 at the time of labor and delivery-interventions such as elective cesarean section performed before the onset of labor [8, 15, 16] ; antiretroviral combinations initiated during pregnancy, to achieve viral suppression at time of delivery; and potent and rapidly acting antiretroviral drugs such as nevirapine, administered during labor [31] , although preand/or postexposure of the fetus/neonate to HIV-1 could be the main mechanism explaining the efficacy of intrapartum prophylaxis with nevirapine.
Although the interpretation of the association between factors known at baseline and transmission is relatively straightforward, one should be cautious when looking at the association between events occurring later during pregnancy and transmission. For example, although an association between prolonged rupture of membranes and intrapartum transmission has been previously reported [14, 20, 34] , we did not find this association in our analysis. Induction of labor, however, remained associated with the risk of intrapartum transmission even after adjustment for HIV-1-load level, premature rupture of membranes, and prolonged labor, an observation that has not been reported elsewhere. It is not possible to definitely rule out other confounders. Similarly, it is difficult to draw any causal inference from the significant association between premature labor with tocolysis, performed in only 12 cases, and intrapartum transmission.
In conclusion, the present study confirms the importance of the time of transmission for the design of preventive interventions to ensure efficacy while minimizing the risks associated with unnecessary exposure of the fetus/neonate to antiretroviral therapy. To prevent in utero transmission, initiation of antiretroviral prophylaxis at 28 weeks gestation appears to be crucial. The fact that intrapartum transmission was found to occur at relatively low levels of maternal HIV-1 load suggests that minimizing exposure to HIV and/or ensuring efficient pre-/postexposure antiretroviral prophylaxis is of paramount importance at the time of labor and delivery.
